BioCryst Pharmaceuticals, Inc.BCRXNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+178.4%
Year-over-Year Change
Year-over-year operating cash flow growth rate
3Y CAGR
+178.4%/yr
Quarterly compound
Percentile
P97
Near historical high
vs 3Y Ago
21.6x
Strong expansion
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 571.44% |
| Q3 2025 | -0.46% |
| Q2 2025 | 250.10% |
| Q1 2025 | -427.85% |
| Q4 2024 | -163.23% |
| Q3 2024 | 702.70% |
| Q2 2024 | 97.45% |
| Q1 2024 | -501.97% |
| Q4 2023 | 55.18% |
| Q3 2023 | -5.76% |
| Q2 2023 | 60.40% |
| Q1 2023 | -99.22% |
| Q4 2022 | 26.49% |
| Q3 2022 | -16.89% |
| Q2 2022 | 64.32% |
| Q1 2022 | -139.69% |
| Q4 2021 | -39.45% |
| Q3 2021 | 8.40% |
| Q2 2021 | 58.35% |
| Q1 2021 | -36.68% |
| Q4 2020 | -16.69% |
| Q3 2020 | -23.24% |
| Q2 2020 | -33.33% |
| Q1 2020 | -122.83% |
| Q4 2019 | 62.20% |
| Q3 2019 | -12.80% |
| Q2 2019 | 9.25% |
| Q1 2019 | -12.56% |
| Q4 2018 | 31.53% |
| Q3 2018 | -152.12% |
| Q2 2018 | 29.30% |
| Q1 2018 | -86.83% |
| Q4 2017 | 15.37% |
| Q3 2017 | -28.58% |
| Q2 2017 | -13.37% |
| Q1 2017 | -45.66% |
| Q4 2016 | 66.66% |
| Q3 2016 | -56.99% |
| Q2 2016 | 40.64% |
| Q1 2016 | -27.07% |